American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Rosen
    Rosen
  3. Hudis
    Hudis
  4. Scher
    Scher
  5. Berger
    Berger
  6. Ladanyi
    Ladanyi
  7. Kris
    Kris
  8. Chandarlapaty
    Chandarlapaty
  9. Robson
    Robson
  10. Norton
    Norton

Groups

  1. Department of Medicine (2072)
  2. Solid Tumor Oncology Division (1735)
  3. GSK Faculty (1035)
  4. Breast Medicine Service (605)
  5. Human Oncology and Pathogenesis Program (522)
  6. Genitourinary Oncology Service (513)
  7. Sloan Kettering Institute Postdocs (465)
  8. Sloan Kettering Institute Faculty (440)
  9. Department of Pathology and Laboratory Medicine (420)
  10. Hematologic Malignancies, Division of (419)
Search Within
  1. "Department of Medicine"
Formats
  1. Meeting Abstract (1072)
  2. Journal Article (947)
  3. Editorial (28)
  4. Review (17)
  5. Conference Paper (3)
  6. Miscellaneous (3)
  7. Correspondence (1)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2072)
  2. Solid Tumor Oncology Division (1735)
  3. GSK Faculty (1035)
  4. Breast Medicine Service (605)
  5. Human Oncology and Pathogenesis Program (522)
  6. Genitourinary Oncology Service (513)

More Groups

People
  1. David Solit (174)
  2. Neal Rosen (141)
  3. Clifford Hudis (140)
  4. Howard Scher (139)
  5. Larry Norton (108)
  6. Michael Berger (103)

More People

Years
  1. 2025 (3)
  2. 2024 (38)
  3. 2023 (46)
  4. 2022 (168)
  5. 2021 (172)
  6. 2020 (187)

More Years

Publications
  1. Cancer Research (1231)
  2. Clinical Cancer Research (841)

Results (2072)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ER pathway activity signature as a biomarker for endocrine agent GDC-9545
    Meeting Abstract

    Daemen, A.; Spoerke, J. M.; Zhou, W.; Guan, J.; Ingalla, E.; Young, A.; Hafner, M.; Aimi, J.; Chang, C. W.; Giltnane, J. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Mechanisms of resistance to CDK4/6 inhibitors and new therapeutic approaches
    Meeting Abstract

    Chandarlapaty, S.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Initial real world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer
    Meeting Abstract

    Carter, G. C.; Sheffield, K. M.; Gossai, A.; Huang, Y. J.; Zhu, Y. E.; Bowman, L.; Smith, E. N.; Mathur, R.; Cohen, A. B.; Baxi, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase 1/2 dose-escalation and expansion study investigating SAR439859, a potent, oral, selective estrogen receptor degrader, +/- palbociclib in metastatic breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Celanovic, M.; Linden, H. M.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Ming, J.; Celanovic, M.; Linden, H. M.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer
    Journal Article

    Schoenfeld, A. J.; Chan, J. M.; Kubota, D.; Sato, H.; Rizvi, H.; Daneshbod, Y.; Chang, J. C.; Paik, P. K.; Offin, M.; Arcila, M. E.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase II TRITON2 study
    Journal Article

    Abida, W.; Campbell, D.; Patnaik, A.; Shapiro, J. D.; Sautois, B.; Vogelzang, N. J.; Voog, E. G.; Bryce, A. H.; McDermott, R.; Ricci, F.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Patient-reported outcomes from the phase III randomized IMmotion151 trial: Atezolizumab + bevacizumab versus sunitinib in treatment-naïve metastatic renal cell carcinoma
    Journal Article

    Atkins, M. B.; Rini, B. I.; Motzer, R. J.; Powles, T.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Gurney, H.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions
    Journal Article

    Sato, H.; Schoenfeld, A. J.; Siau, E.; Lu, Y. C.; Tai, H.; Suzawa, K.; Kubota, D.; Lui, A. J. W.; Qeriqi, B.; Mattar, M.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer
    Journal Article

    Middleton, G.; Yang, Y.; Campbell, C. D.; André, T.; Atreya, C. E.; Schellens, J. H. M.; Yoshino, T.; Bendell, J. C.; Hollebecque, A.; McRee, A. J.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: